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Summary We have examined the ability of eight compounds to enhance adriamycin (ADM) sensitivity of
two human tumour cell lines (a small cell lung cancer cell line, NCI-H69, and a fibrosarcoma cell line,
HT1080) and their multidrug-resistant variants. The resistant cell lines (H69AR and HT1080/DR4) do not
overexpress P-glycoprotein. Verapamil, nicardipine, perhexiline maleate, chloroquine, tamoxifen, clomiphene,
prenylamine and trifluoperazine were tested alone and in combination with ADM for their cytotoxic effects.
No major differences in sensitivity between the parent and resistant cell lines were noted when these agents
were tested alone, except for HT1080/DR4 cells which exhibited a slight collateral sensitivity to nicardipine
and H69AR cells which showed cross-resistance to chloroquine and clomiphene. When the chemosensitisers
were combined with ADM no enhanced cytotoxicity of either parent cell line was observed. In HT1080/DR4
cells, verapamil showed only a modest dose-dependent chemosensitising effect while the other compounds had
no effect. Verapamil and nicardipine enhanced ADM cytotoxicity in H69AR cells slightly but these effects
were not dose-dependent. These results demonstrate that the reversal of drug resistance by verapamil and
other calcium antagonists in a dose-dependent fashion is not an invariable property of multidrug-resistant
tumour cells.
One of the major reasons for eventual treatment failure in
initial responsive tumours is the appearance and prolife-
ration of multidrug-resistant (MDR) tumour cells. A large
number of mammalian cell lines have been described which
exhibit the MDR phenotype and thus provide a model for
the study of this clinical problem. Even though selected with
a single agent, these cell lines are resistant to a wide range of
chemically and functionally unrelated drugs. A variety of
biochemical changes in MDR cells have been described but
the most consistent alteration has been the increased expres-
sion of a high molecular weight plasma membrane glycopro-
tein (Gerlach et al., 1986). This protein was first described
by Ling & Thompson (1974) in Chinese hamster ovary
(CHO) cells and has been termed P-glycoprotein. Consider-
able evidence suggests that this protein is responsible for
increased efflux of drug from MDR cells (Gros et al., 1986).
Enhanced P-glycoprotein expression has been detected in
tumour samples from MDR patients with ovarian carcinoma
(Bell et al., 1985), leukaemias (Ma et al., 1987) and fibrosar-
comas (Gerlach et al., 1987) indicating that the phenomenon
occurs in humans as well. While P-glycoprotein has clearly
been shown to play an important role in MDR, it is unlikely
that it is solely responsible for MDR in all tumour cells
(Kaye & Merry, 1985). In fact, several human cell lines
displaying an MDR phenotype have recently been described
in which no evidence of enhanced P-glycoprotein expression
can be found by immunoassay or RNA blotting methods
(Slovak et al., 1988; Mirski et al., 1987; Marsh & Center,
1987; Trent et al., 1988).
Tsuruo et al. (1981) were the first to report that verapamil
(VP), a calcium channel blocker, could reverse MDR in
vitro. A variety of compounds have since been identified
which enhance drug sensitivity in vitro and are often referred
to as 'chemosensitisers'. Included in this group are such
diverse compounds as nicardipine (Ramu et al., 1984c),
trifluoperazine (Ganapathi & Grabowski, 1983), tamoxifen
(Ramu et al., 1984b), quinidine (Tsuruo et al., 1984), reser-
pine (Inaba et al., 1981), chloroquine (Zamora & Beck,
1986), propranolol (Shiraishi et al., 1986), perhexiline
-Tnaleate (Ramu et al., 1984a), synthetic isoprenoids
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(Yamaguchi et al., 1986), cyclosporin A (Slater et al., 1986)
and local anaesthetics (Chlebowski et al., 1982). While most,
if not all, of these compounds affect calcium metabolism, it
is generally agreed that the ability of these agents to enhance
chemosensitivity results from interactions with a membrane
transport system and not via modulation of calcium fluxes
(Ramu et al., 1984a, c; Kessel & Wilberding, 1984). Despite
the fact that the mode of action of chemosensitisers is not
yet understood (Hindenburg et al., 1987; Harker et al., 1986;
Ganapathi et al., 1986), these chemicals are being evaluated
in clinical trials (Ozols et al., 1987; Dalton et al., 1987, 1989;
Tormey et al., 1982).
Many of the cell lines in which reversal of resistance has
been demonstrated have also been shown to express
enhanced levels of P-glycoprotein (Zamora & Beck, 1986;
Hamada et al., 1987; Tsuruo et al., 1981). The present study
was undertaken to determine whether or not adriamycin
(ADM) resistance could be pharmacologically reversed in
two MDR human tumour cell lines which lack elevated
P-glycoprotein.
Materials and methods
Drugs
Chloroquine diphosphate, clomiphene citrate, nicardipine,
perhexiline maleate, tamoxifen citrate, trifluoperazine dihyd-
rochloride, prenylamine, verapamil hydrochloride and MTT
[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium brom-
ide] were obtained from Sigma Chemical Co. (St Louis, MO,
USA). Adriamycin (Doxorubicin, HCI; ADM) was obtained
from Adria Laboratories (Burlington, Ontario) through the
Kingston Cancer Clinic pharmacy.
Cell culture
The human small cell lung cancer (SCLC) cell line NCI-H69
(H69) was kindly provided by Dr J. Minna (National Cancer
Institute, Bethesda, MD, USA). A MDR variant of H69,
designated H69AR, was established by culturing the sensitive
cells in increasing concentrations of ADM and has been
described previously (Mirski et al., 1987). These cell lines
were maintained in RPMI 1640 medium (GIBCO) supple-
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mented with 5% heat-inactivated fetal bovine serum (FBS)
and 4mM L-glutamine. H69AR was challenged biweekly with
0.6Mm ADM.
The human fibrosarcoma cell line HT1080 and the deriva-
tion of its MDR variant HT1080/DR4 are described else-
where (Slovak et al., 1988). These cell lines were maintained
in minimal essential medium (GIBCO) supplemented with
10% FBS, 4mM L-glutamine and non-essential amino acids
(GIBCO) (0.1 mM). HT1080/DR4 cells were cultured in
0.2gM ADM at all times except for the 48 h before drug
additions when the medium was replaced with that contain-
ing no ADM. All cell lines were cultured at 37°C under 5%
CO2' Cultures were checked for Mycoplasma contamination
using the 4',6-diamidino-2-phenylindole DNA-binding
method (Russell et al., 1975) and found to be negative.
MTT assay
Chemosensitivity was determined using the MTT assay
(Mosmann, 1983; Cole, 1986; Mirski et al., 1987). The
human fibrosarcoma cell lines were harvested by incubation
in citrated phosphate-buffered saline (PBS) for 10min at
37°C, while H69 and H69AR cells were harvested by centri-
fugation. After resuspension in fresh medium, the cells were
plated in a volume of 100ul at 5 x 103 cells per well for
HT1080 and HT1080/DR4 and 2.5 x 104 cells per well for
H69 and H69AR in 96-well plates. These cell densities were
chosen because they allowed exponential growth throughout
a five-day assay period. The plates were incubated at 37°C
overnight and then ADM and chemosensitisers were added
in a total volume of 100,l and the plate incubated at 370C
for a further five days.
The chemosensitisers were dissolved in methanol, except
for trifluoperazine which was dissolved in dimethyl sulphox-
ide and chloroquine which was dissolved in tissue culture
medium. Stock solutions were diluted in RPMI 1640 5%
FBS medium as required and were prepared freshly for each
experiment. Three hours before the end of the drug exposure
time, 100pl of medium was removed from each well, 25pl of
MTT (2mgml-1 in PBS) were added and the plate incu-
bated at 37°C for an additional 3 hours. One hundred pl of
1 NHCl: isopropanol (1:24) was added to each well followed
by thorough mixing with a multichannel pipette and a
further 1 h incubation at 37°C to aid solubilisation of the
formazan crystals. The absorbance at 570nm was determined
using a Dynatech MR600 microplate reader. Within each
experiment, determinations were done in quadruplicate and
each drug was tested in two or more separate experiments.
Controls consisted of wells with no cells and wells with cells
plus vehicle (baseline). In the combination experiments, wells
with cells plus chemosensitiser but no ADM were also
included as controls.
Results are expressed as a percentage of the baseline
absorbance at 570nm and an ID was defined as the dose
of drug which reduced absorbance to 50% of control values.
Only those combination experiments in which the chemo-
sensitiser alone reduced the baseline absorbance by less than
20% are reported. An ADM dose-response curve was
determined in each experiment. Throughout these series of
experiments the relative resistance of H69AR cells to ADM
ranged from 20 to 141-fold while the relative resistance of
HT1080/DR4 cells ranged from 45 to 333-fold. The mean
relative resistance (+s.e.m.) of H69AR and HT1080/DR4
cells was 66+12 (n= 12) and 88+21 (n= 14), respectively. In
some experiments, low doses of ADM appeared to cause a
small (20%) stimulatory effect on the growth of H69AR
cells. This effect was not seen with the other cell lines. The
basis of this stimulation is unknown but may be similar to
that described by Grace et al. (1987).
Results
Eight drugs were tested for their ability to reverse ADM
cytotoxicity in two human tumour cell lines (HT1080 and
H69) and their-multidrug-resistant variants which do not
overexpress P-glycoprotein (HT1O8O/DR4 and H69AR).
These drugs included calcium channel blockers (VP, nicardi-
pine, perhexiline maleate), calmodulin inhibitors (trifluopera-
zine, prenylamine), anti-oestrogens (clomiphene, tamoxifen)
and the anti-malarial agent, chloroquine.
In the first series of experiments, dose-response curves
were determined for the chemosensitisers. The results for
HT1080 and HT1O8O/DR4 cells are shown in Figure 1 and
the results for H69 and H69AR cells are shown in Figure 2.
From these experiments it was determined that the maximal
non-toxic doses of chemosensitisers for HT1O8O/DR4 cells
were VP 1OuM, chloroquine 1OUM, trifluoperazine 3/M,
clomiphene 3gM, tamoxifen 1 pM, prenylamine 1 gM, nicardi-
pine 3 Mm and perhexiline maleate 1 gM. HT1080 cells were
equally sensitive to the chemosensitisers, except for nicardi-
pine which was slightly more cytotoxic to HTIO8O/DR4 cells
than HT1080 cells (Figure 1). The maximal non-toxic doses
for H69AR cells were VP 1O Mm, trifluoperazine 1 UM, clomi-
phene 1 Mm, tamoxifen 3 Mm, prenylamine 1 Mm, nicardipine
3Mm and perhexiline maleate 1Mm. H69 cells were equally
sensitive to all drugs except chloroquine and clomiphene.
H69 cells were slightly more sensitive to clomiphene than
H69AR cells, while H69AR cells exhibited considerable
cross-resistance to chloroquine (Figure 2).
In the second series of experiments, the combined effect of
ADM and chemosensitiser on the viability of the fibrosar-
coma cell lines was determined at non-toxic doses of chemo-
sensitiser. The results are shown in Table I. Of the eight
drugs tested, only VP had any significant chemosensitising
effect on HT1O8O/DR4 cells and appeared to do so in a
dose-dependent manner. However, this effect was modest.
Thus IOMm and I MM VP reduced the IC50 of ADM 7.4-fold
and 4.2-fold, respectively, in HT1080/DR4 cells. The effect
in HT1080 cells was not significant. These results are in
excellent agreement with those obtained independently by
Slovak et al. (1988) using a slightly modified MTT assay
(Carmichael et al., 1987).
In the last series of experiments, the combined effect of
ADM and chemosensitiser on the viability of the SCLC cell
lines was determined. The results are shown in Table II.
None of the drugs enhanced the cytotoxic effects of ADM
on H69 cells. Chloroquine, trifluoperazine, clomiphene and
tamoxifen did not enhance the sensitivity of H69AR cells
while VP, prenylamine, nicardipine and perhexiline maleate
caused a very modest (maximum 4.9-fold) reversal of resis-
tance in H69AR cells. However, in no case was this effect
dose-dependent.
Discussion
The development of drug resistance in cancer patients is
widely recognised as a major impediment to successful
chemotherapy. Thus the discovery that the calcium channel
blocker VP could reverse MDR in an experimental system
was an important finding since it has provided a strategy for
treating this clinical problem.
Many structurally diverse chemosensitisers in addition to
VP have been identified in experimental systems. However,
no single agent has been demonstrated to be clearly superior
to others nor has the mode of action of these compounds
been elucidated. In fact, current evidence suggests that
chemosensitising agents may act by different mechanisms
(Kessel, 1986). Despite this lack of information, VP has
made its way into several clinical trials. Ozols et al. (1987)
were unable to find any chemosensitising effect of VP for
ADM in eight drug resistant ovarian cancer patients. On the
other hand, Dalton et al. (1987, 1989) have demonstrated a
therapeutic benefit of VP for four patients with P-
glycoprotein-positive B-cell neoplasms. These findings
demonstrate that it is not yet possible to predict the clinical
usefulness of these agents in a given group of patients.
Furthermore, there is insufficient information to allow the44 S.P.C. COLE et al.
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Figure 1 Effect of chemosensitisers on the growth of human fibrosarcoma cell lines, HT1080 (0) and multidrug resistant
HT1080/DR4 (@) as measured by the MTT assay. Cells were set up at 5 x 103 cells per well on day 0, drugs added on day 1 and
cell viability measured on day 5. Within each experiment, assays were done in quadruplicate. Each point represents the mean of
results from two or more individual experiments which varied < 10%. Error bars represent the s.d. where three or more
experiments were performed.
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Figure 2 Effect of chemosensitisers on the growth of small cell lung cancer cell lines, H69 (0) and multidrug resistant H69AR
(0) as measured by the MTT assay. Cells were set up at 2.5 x 104 cells per well on day 0, drugs added on day and cell viability
measured on day 5. Within each experiment, assays were done in quadruplicate. Each point represents the mean of results from
two or more individual experiments which varied < 10%. Error bars represent the s.d. where three or more experiments were
performed.
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Table I Effect of chemosensitisers on ADM sensitivity of human fibrosarcoma
cell lines HT1080 and HT1080/DR4
Dose modifying factor'
Concentration
Drug CuM) HT1080 HT1080/DR4
Verapamil 10 2.63 (±1.42)b 7.43 (±0.57)
3 2.48 (1.75, 3.20) 4.21 (4.45, 3.96)
1 1.46 (1.11, 1.80) 1.42
Chloroquine 10 1.42 1.27
3 1.01 (±0.51) 1.11 (0.80, 1.41)
1 1.09 (±0.86) 1.23 (±0.73)
Trifluoperazine 3 1.20 (1.26, 1.13) 1.04 (1.27, 0.80)
1 1.01 (1.13, 0.89) 1.21 (1.42, 1.00)
Clomiphene 3 1.41 (±0.15) 1.06 (±0.30)
1 1.13 (±0.14) 1.05 (+0.14)
Tamoxifen 1 0.90 (1.00, 0.80) 1.27 (1.12, 1.42)
Prenylamine 1 0.95 (1.00, 0.90) 0.96 (0.79, 1.12)
0.3 1.01 (1.11, 0.90) 0.88 (0.63, 1.12)
Nicardipine 3 1.25 (1.39, 1.11) 1.06 (1.00, 1.12)
Perhexiline 1 1.50 (1.75, 1.25) 1.26 (1.25, 1.26)
0.3 1.25 (1.39), 1.11) 1.00 (1.00, 1.00)
aDose modifying factor is defined as the ID50 ADM: ID50 (ADM+chemosensi-
tiser); bs.d. given in parentheses where three or more experiments were performed.
The results of individual experiments are given where less than three experiments
were done. Within each experiment, assays were done in quadruplicate.
Table 11 Effect of chemosensitisers on ADM sensitivity of small cell lung cancer
cell lines H69 and H69AR
Dose modifying factora
Concentration
Drug (PM) HT69 HT69AR
Verapamil 10 0.91 (0.82, 1.00)b 4.86 (±1.96)
3 1.08 (+0.52) 1.81 (±1.02)
1 1.24 (±0.70) 2.42 (±0.79)
Chloroquine 3 1.84 (2.54, 1.13) 1.34 (1.41, 1.26)
0.3 0.94 (±0.34) 2.81 (±2.48)
Trifluoperazine 1 2.32 (2.86, 1.78) 1.63 (1.25, 2.00)
0.3 0.80 (±0.41) 1.27 (±0.59)
Clomiphene 1 1.69 (1.80, 1.58) 1.74 (±0.70)
0.3 0.85 (+0.20) 0.99 (±0.59)
Tamoxifen 3 1.13 1.23 (±0.35)
1 1.49 (±1.13) 2.30 (1.42, 3.17)
Prenylamine 1 1.63 (+0.52) 2.59 (±0.72)
0.3 1.85 (±1.50) 3.33 (±1.64)
Nicardipine 3 1.09 (+0.18) 4.59 (5.61, 3.56)
1 1.41 (1.42, 1.40) 4.22 (3.98, 4.48)
Perhexiline 1 0.94 (±0.58) 2.44 (±1.02)
0.3 1.32 (0.63, 2.00) 3.93 (5.04, 2.81)
'Dose modifying factor is defined as the ID50 ADM: ID50 (ADM+ chemosensi-
tiser); bs.d. given in parentheses where three or more experiments were performed.
The results of individual experiments are given where less than three experiments
were done. Within each experiment, assays were done in quadruplicate.
rational selection of the optimal chemosensitiser for each
group.
There are many possible explanations for the contrasting
results reported by Ozols et al. (1987) and Dalton et al.
(1987), including methodological differences. It is also poss-
ible that only certain tumour types respond to the effects of
chemosensitising agents. Another possibility is that only drug
resistance associated with P-glycoprotein is susceptible to
reversal by VP and other compounds (Croop et al., 1987).
The results of the present study support this latter idea since,
of eight different agents tested, only VP (in the case of
HT1080/DR4 cells) and VP and nicardipine (in the case of
H69AR cells) had any ability to enhance ADM cytotoxicity.
In all instances, the enhancing effect was modest and, in the
H69AR cells, the effects were not dose-dependent, suggesting
a limited potential for calcium antagonists to reverse resis-
tance in these cell lines. Neither the HT1080/DR4 cell line
nor the H69AR cell line overexpress P-glycoprotein (Trent et
al., 1988). Further support for this idea comes from the
study of Beck et al. (1987) who found that VP did not
reverse resistance in an 'atypical' (non-P-glycoprotein-
containing) MDR human leukaemic cell line.
The results obtained in the present study with SCLC cell
line H69AR contrast with those of Twentyman et al. (1987).
These investigators were able to show a clear dose-dependent
enhancement of ADM sensitivity by VP in a MDR variant
of NCI-H69, H69/LX4, derived independently from us.
However, it is noteworthy that H69/LX4 cells express ele-
vated levels of P-glycoprotein (J.J. Reeve & P. Twentyman,
personal communication). These results support the idea that
the presence of elevated P-glycoprotein may be a predictor
of response to chemosensitising agents in SCLC and other
cancers. More extensive laboratory and clinical studies are
necessary to test this hypothesis.46 S.P.C. COLE et al.
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